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Abstract: Epidermal growth factor receptor (EGFR) is one of signalling pathways activated during premalignant proliferative
changes in the airway epithelium. However there is no agreement about prognostic significance of EGFR expression in
non-small cell lung cancer (NSCLC). Facts mentioned above prompted us to study EGFR expression in the group of 78
surgically treated squamous cell lung cancer (SqCLC) patients. The EGFR expression was visualized in formalin-fixed,
paraffin-embedded sections, using immunohistochemistry. Three methods of assessment of EGFR expression were applied:
percentage of cells with membranous EGFR expression - EGFR labellig index (EGFR LI), percentage of fields with
membranous EGFR staining (PS%) and staining intensity (absent, weak or strong) in the whole specimen (SI). Mean EGFR
LI and PS% values were 30.4 ± 3.5% and 51.6 ± 3.9%, respectively. Patients with higher EGFR expression (EGFR LI, PS%,
SI) were significantly younger than those with low EGFR expression. EGFR LI was higher in pT3 tumours than in pT1+pT2
tumours, moreover, EGFR expression (EGFR LI, PS%, SI) was significantly higher in G1+G2 tumours than in G3 tumours.
There were significant correlations between parameters used for assessment of EGFR expression. PS%≤50 indicated shorter
disease-specific survival than PS%>50. However, patients with tumours with both very low and very high EGFR LI
(13%≥EGFR LI>80%) showed significantly shorter survival than those with medium EGFR LI (13%<GFR LI≤80%).
Additionally, pTNM and pN significantly influenced patients’ survival. In multivariate analysis, EGFR LI and pTNM were
independent prognostic parameters influencing disease-specific survival of patients.
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Introduction
Lung cancer (LC) is the most common cause of deaths
among all malignant neoplasmas all over the world. The
results of surgery are still not satisfactory. Patients after
potentially curative surgery, with the same pathological
stage of disease, display marked variability in recurrence
and survival [29]. This prompts many authors to study
the biology of LC. The following prognostic factors
have been studied: DNA ploidy [21], proliferative activ-
ity of tumour cell [17], mutation and expression of
proto-oncogens, loss of blood group antigens on tumour
cells, loss of tumour suppressor gene function, an-
giogenesis and others [19]. 
Epidermal growth factor receptor (EGFR) family is
one of the best described signalling pathways activated
during premalignant proliferative changes in the airway
epithelium [14]. EGFR (ErbB-1) was found to be over-
expressed in many types of squamous cell cancers, as
well as in squamous cell lung cancer (SqCLC) [5, 9, 13,
31, 35]. Amplified EGFR signalling might induce cell
growth and increase the metastatic potential of the tu-
mour [37]. These facts suggest that EGFR expression
might be a prognostic factor. In head and neck, ovarian,
cervical, bladder and oesophageal cancers, the associ-
ation between elevated EGFR level and poor patient
outcome is particularly strong [28]. Not so strong rela-
tion has been noted in gastric, breast, endometrial and
colorectal cancers [28]. In contrast, there is no agree-
ment about prognostic significance of EGFR expression
in NSCLC [10, 12, 28, 33, 36, 38]. This disagreement
might be caused by lack of standard methods assessing
EGFR expression and by histological heterogeneity of
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the analysed NSCLC groups. The latter cause is highly
probable, as expression of EGFR is stronger in SqCLC
than in adenocarcinomas and large cell carcinomas of
lung [35, 13]. This might indicate different biology of
different histological types of NSCLC. The facts men-
tioned above prompted us to analyse prognostic signi-
ficance of three parameters applied for assessment of
EGFR expression in a group of SqCLC patients. Recent-
ly, new EGFR-targeting anticancer agents are tested in
clinical trials [1, 3, 6, 23, 24, 39]. Thus, development of
simple and reliable methods measuring the level of
EGFR expression could be helpful in selecting patients
who might be qualified for the above treatment. 
Materials and methods
Patients. Between 1986-1999, seventy-eight patients with stage
I-IIIA SqCLC were treated with radical surgery according to com-
monly accepted criteria [2, 25]. The mean age of patients was 58.9
± 0.9 yrs (range 41-73 yrs). There were 71 men and 7 women, without
difference between the mean age of males and females. None of the
patients had been treated with radio- or chemotherapy before surgery.
All the patients were operated on by the same surgeon. Thirty-nine
patients underwent lobectomy, and 39 pneumonectomy, assessed as
radical by the surgeon and pathologist [2, 25]. Mediastinal lym-
phadenectomy was performed only in suspected cases (enlargement
of mediastinal lymph nodes or histologicaly confirmed metastases)
- in the other patients only sampling was carried out [26, 27].
Nineteen patients were subjected to postoperative radiotherapy and
two to chemotherapy. The clinical (TNM) and pathological (pTNM)
stages were established according to TNM UICC 1997 criteria [34].
The stage and grading of the tumours are summarized in Table 1.
Each patient was followed-up from surgery till death (for the purpose
of this study follow-up was finished at 5th year). Thirty patients died:
7 patients (23.3%) of local cancer recurrence, 23 (76.7%) of distant
metastases. Forty seven patients are still alive without progression of
SqCLC, one is alive with metastases. The study has been approved
by the Ethical Committee of the Centre of Oncology.
Material. Immediately after excision, fresh specimens (about 0.5
cm2) from each patient were fixed in 10% neutral buffered formalin
and embedded in paraffin for routine light microscopic analysis. The
slides were examined by a pathologist in order to establish histology
and grading.
Immunohistochemistry. Sections were cut at 4 µm, mounted on
Super Frost® Plus (Menzel-Gläser, Germany) slides and then depar-
affinized and hydrated through a series of xylenes and alcohols.
Before staining, the sections were digested for 15 min at room
temperature with DAKO® ready-to-use proteinase K (DAKO Ltd.,
proteolytic enzyme solution diluted in 0.05 M Tris-HCl, 15 mM
sodium azide, pH 7.5). Then, the sections were rinsed in Tris-buf-
fered saline (TBS), pH 7.4. Endogenous peroxidase activity was
blocked by 0.03% hydrogen peroxide containing sodium azide
(DAKO EnVisionTM+ system; DAKO Ltd.). Nonspecific binding of
immunoglobulins was blocked by 20% normal swine serum (DAKO
Ltd.). Next, slides were incubated for 40 min at room temperature
with monoclonal mouse anti-human EGFR, clone H11 (DAKO Ltd.)
which was diluted 1/200 in antibody diluent (DAKO Ltd.). DAKO
EnVisionTM+ system was used to visualise the anti-EGFR antibody.
Sections were counterstained with hematoxylin. For negative con-
trol, TBS was substituted for the primary antibody. Positive controls
were performed on SqCLC sections known to exhibit membranous
overexpression of EGFR.
Evaluation of EGFR expression. Assessment of EGFR expression
was based on EGFR protein staining in membranes of tumour cells.
Three methods were used: SI - staining intensity within the whole
specimen, PS% - percentage of fields with positive staining for
EGFR, and EGFR LI (EGFR labelling index) - the percentage of cells
with positive staining. The first method - SI was assessed after
scanning of the whole specimen at × 200 magnification. Membran-
Table 1. Correlations between clinicopathological parameters and parameters used for EGFR assessment in SqCLC patients
Pathological 
parameter N
EGFR LI (%)
mean ± SE
PS (%)
mean ± SE
SI
absent or weak 
membranous staining - no.
of cases (percentage) 
strong membranous
staining - no. of
cases (percentage)
TNM stage
I
II
III
40
26
12
30.8 ± 5.2
26.0 ± 5.2
28.4 ± 9.5
53.4 ± 5.6
50.6 ± 6.2
48.3 ± 12.1
15 (19.2)
11 (14.1)
 5 ( 6.4)
25 (32.1)
15 (19.2)
 7 ( 9.0)
pT
pT1+pT2 
pT3
1+62
15
27.8 ± 3.9
41.0 ± 7.5 a
47.9 ± 4.5
67.3 ± 6.9
28 (35.9)
 3 ( 3.8)
35 (44.9)
12 (15.4)
pTNM stage
I
II
III
32
31
15
33.6 ± 5.6
23.8 ± 4.9 
37.1 ± 8.8
55.3 ± 6.1
44.0 ± 6.3
59.7 ± 9.1
12 (15.4)
13 (16.7)
 6 ( 7.7)
20 (25.6)
18 (23.1)
 9 (11.5)
Grade*
G1+ G2
G3
14+25
38
41.0 ± 5.1
20.2 ± 4.2 b
66.7 ± 4.8
37.1 ± 5.5 b
 9 (11.7)
21 (27.3)
30 (38.9)
  17 (22.1) b
*in one case grade was not assessed; 
a - pT1+pT2 vs. pT3; p=0.0432 (for EGFR LI); 
b - G1+G2 vs. G3; p=0.0010 (for EGFR LI); p=0.0003 (for PS); p=0.0039 (for SI)
112 J. Niemiec et al.
Fig. 1. Expression of epidermal growth factor receptor in squamous cell lung cancer. A, B: strong membranous EGFR expression in all
tumour cells; C: weak membranous EGFR expression (arrows) in a few tumour cells; D: no EGFR expression in all tumour cells. × 630. 
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ous staining was considered strong (Fig. 1A, B), weak (Fig. 1C) or
negative (Fig. 1D). In the mentioned above qualitative method,
positive control slide showing strong membranous staining was used
as a reference sample. In case of not uniform staining intensities in
the specimen, the highest grade of intensity was considered. The
second method - PS% was assessed in ten randomly selected fields
(at × 400 magnification) and was computed as number of fields with
positive membranous staining (weak or strong) divided by 10 (the
number of examined fields). PS% was expressed as percentage. The
third method - EGFR LI was assessed in ten randomly selected fields
(at × 400 magnification), and computed as a number of cells with
positive membranous staining for EGFR (weak or strong) divided by
the number of all cells that were counted. EGFR LI was expressed
as a percentage. The person involved in the EGFR expression assess-
ment was not aware of the clinical outcome and follow-up status of
patients. 
Statistical analysis. Descriptive statistics were used to determine
mean values of EGFR LI and standard error of mean (SE). The
normality of EGFR LI distribution was assessed using Shapiro-Wilk
W test. The statistical significance of differences between the means
was assessed by Mann-Witney U test, (in case of variables with not
normal distribution) and with the Student t-test (in case of variables
with normal distribution). The Pearson χ2 test was used to analyse
the associations between categorical variables. In all statistical pro-
cedures, p values lower than 0.05 were considered significant. Dis-
ease-specific survival (the patients whose cause of death was not
malignancy were treated as alive) was analysed. The probability of
survival was calculated using the Kaplan-Meyer method [20]. The
first step in the analysis of prognostic factors was univariate analysis
done using the log-rank test. Because mean or median values for
EGFR LI were not important, the optimal cut-off points, (’minimal’
p values) were chosen by log-rank test. Covariates that in univariate
analysis were significantly related to outcome variable, were entered
into multivariate analysis. The joint effect of remaining covariates,
were analysed using Cox proportional hazard model and stepwise
regression procedure [7]
Results
In the analysed group of 78 SqCLC, strong membranous
staining for EGFR was found in 47 cases (60.3%) and
weak staining in 21 cases (26.9%). In 10 cases (12.8%),
Fig. 2. Correlation between EGFR expression and patients’ survival
after surgery. A: patients survival according to EGFR labelling
index; B: survival as a function of positive staining for EGFR (PS%),
stratified using the PS%≤50% and PS%>50%.
Fig. 3. Correlation between clinical parameters and patients’ survival
after surgery. A: correlation between pN and patients’ survival; B:
correlation between pTNM and patients’ survival. 
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membranous staining was absent. The EGFR LI ranged
from 0 to 100% with a mean value of 30.4% ± 3.5. Mean
EGFR LI for 68 tumours (87.2%) with positive (weak
or strong) membranous staining for EGFR was 34.8 ±
3.7. PS% ranged from 0 to 100%, with a mean value of
51.6% ± 3.9. The variables, EGFR LI and PS%, did not
show normal distribution (p<0.0000). As expected, tu-
mours with strong membranous staining had significant-
ly higher values of EGFR LI and PS% (47.5 ± 4.1, 70.2
± 3.9 respectively) than tumours with weak staining (6.5
± 1.5, 34.8 ± 5,1 respectively), (p=0.0000). Moreover,
correlation between PS% and EGFR LI has been found
(p=0.000). 
There was no association between EGFR expression
and gender of patients. Significant correlation between age
and EGFR LI or PS% was found (p=0.009, 0.019) - older
patients had lower EGFR LI and PS%. Moreover, patients
with tumours having strong membranous EGFR staining
were significantly younger (p=0.0217), (mean age 57.3 ±
1.1 years) than those with tumours having weak or
absent membranous staining for EGFR (62.2 ± 1.3).
There was no association between T, N, TNM, pN,
pTNM and EGFR expression. However, significantly
higher EGFR LI was found for pT3 than for pT1+pT2
tumours (Tab. 1). All parameters: EGFR LI, PS% and
SI showed higher values in well and moderately dif-
ferentiated tumours (G1+G2) than in poorly differen-
tiated tumours (G3), (Tab. 1).
EGFR LI was significantly higher in tumours from 6
patients, who later suffered from loco regional recur-
rence than in 25 patients who suffered from metastases
(56.9 ± 15.7 vs. 24.8 ± 6.8 respectively), (p=0.0404). 
The Kaplan-Meier estimated 5-year disease-specific
survival was 55%. In univariate analysis, 36 patients
with EGFR LI ranging between 13% and 80% survived
significantly longer than 34 patients with EGFR LI
lower than 13% or 8 patients with EGFR LI higher than
80% (p=0.0003, p=0.0001 respectively). There was no
difference in length of survival between patients with
EGFR LI≤13% and those with EGFR LI>80% (p=0.3).
This prompted us to join the two groups into one:
13≥EGFR LI>80% (Fig. 2A, Tab. 2). Patients with
PS%≤50%, survived significantly shorter than those
with PS%>50% (p=0.0195), (Fig. 2B, Tab. 2). Also
patients with pN1+pN2 tumours survived significantly
shorter than those with pN0 tumours (p=0.0126), (Fig.
3A, Tab. 2). Pathological stage was the next factor that
significantly influenced patients’ survival (p=0.0117),
(Fig. 3B, Tab. 2). Other factors: SI, clinical stage, patho-
logical grade, radiotherapy, chemotherapy were not sig-
nificant in univariate analysis.
In Cox multivariate analysis, only EGFR LI and
pTNM were significant for disease-specific survival
(Tab. 3).
Discussion
The main goal of this study was the assessment of EGF
receptor expression using three methods (based on num-
ber of cells positively stained for EGFR and on staining
intensity) and estimation of their prognostic signific-
ance. Only SqCLC were analysed. In our study, positive
EGFR staining was found in 87.2% of cases. In SqCLC,
Cerney et al. [5] found EGFR expression in 85.7% of
cases, Veale et al. [35] in 87.5%, Pfeiffer et al. [31] in
94.1%, Pastorino et al. [30] in 59% and Cox et al. [9] in
38.1% of analysed cases. In our study, the mean value
of EGFR LI was 30.4% ± 3.5 while in the study of
Fontanini et al. [13] it was 42.1 ± 26.2. Other authors
did not show EGFR expression as an absolute percent-
age, instead they classified tumours into groups with
Table 2. Univariate analysis for SqCLC patients treated with
surgery. Data for 5-year disease-specific survival
Parameter N
The Kaplan-
Meier 
estimated 
5-yr survival
(%)
Median
survival
(months)
(log-rank
test) 
p value
EGFR LI
13%<GFR LI≤80%
13%≥EGFR LI>80%
36
42
82
33
-
16 0.0000
PS%
>50%
≤50%
38
40
4368 -
25 0.0195
TNM
I
II
III
40
26
12
58
48
55
-
42
- 0.9
pN
pN0
pN1 + pN2
38
33+7
70
42
-
23 0.0126
pTNM stage
I
II
III
32
31
15
73
51
29
-
-
14 0.0117
Table 3. Final results of Cox multivariate analysis. Disease-specific
survival for 78 SqCLC patients treated with radical surgery 
Final results
Parameter RR* (Cox proportional hazards)p value
EGFR LI
13%<GFR LI≤80%
13%≥EGFR LI>80%
1
6.7 0.0001
pTNM
I + II
III
1
3.3 0.0030
*RR - relative risk
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different EGFR protein expression [8, 9, 10, 30, 31, 33]
or analysed staining intensity only [18]. 
We found significantly higher EGFR LI values for
well and moderately differentiated than for poorly dif-
ferentiated tumours. Our results are in agreement with
those of Dazzi et al. [10] who found strong EGFR
expression more often in well-differentiated tumours
than in less differentiated and undifferentiated ones.
Other authors found inverted correlation [9] or did not
find any correlation between tumour grade and EGFR
expression [4, 13, 31, 32, 35].
Significantly higher EGFR expression in pT3 tu-
mours than in pT1+pT2 tumours found in our study, was
not observed by other investigators [4, 11, 13, 16]. We
noted lower EGFR expression in older patients, whereas
Cox et al. [9] found inverted relation, and other authors
did not find any association between age and EGFR
expression [16, 31, 32].
In our and other authors’ results there was no signi-
ficant relationship between EGFR level and gender,
TNM, pTNM [4, 9, 11, 31, 32]. However, Fujino et al.
[16] and Veale et al. [35] found significantly lower
EGFR expression in early stage cancers (pI+pII, I+II re-
spectively) than in advanced stage cancers (pIII+pIV, III).
In our study, patients with tumours with EGFR LI
between 13% and 80% survived significantly longer
than those with EGFR LI less than 13% and more than
80%. This fact might indicate that during progression of
SqCLC, a cancer cell may overexpress or not express
EGFR protein on cell membrane. Patients with tumours
with PS%≤50% survived (or survived without evidence
of disease) significantly shorter than patients with
PS%>50%. It is possible that this method is not sensitive
enough to distinguish the group of patients with very
high EGFR expression and poor prognosis. The least
sensitive (qualitative) method, SI, based on intensity of
EGFR staining, was not correlated with disease-specific
survival of patients. 
In the literature, there is still a disagreement about
prognostic significance of EGFR expression in NSCLC
patients (Tab. 4). In most studies, EGFR expression was
not correlated with patients survival [4, 8, 9, 12, 15, 18,
31, 32]. However, some authors found EGFR overex-
pression as a positive [33] and some as a negative [30,
36, 38] factor influencing patients’ survival. Findings
mentioned above may confirm, to some extent, our
results, as we found that both very high (EGFR LI>80%)
and low (EGFR LI≤13%) EGFR expressions had nega-
tive impact on patients’ survival. In our opinion, meth-
ods applied by all quoted above authors, based on
classification of tumours into groups with different
EGFR expression (for example: no staining, P%, <80%
≥80%of stained cells [31]), might cause oversight of
groups with very low or very high EGFR expression. In
our study, oversight of the group of tumours with very
high EGFR expression and poor prognosis occurred,
when we applied a method based on percentage of
positively stained fields (PS%). Using the least sensitive
method, SI, it was impossible to show correlation be-
tween EGFR expression and patients’ survival.
Table 4. Relation between EGFR expression and survival of NSCLC patients after surgery (literature data)
Authors Year No. of patients
Method of
EGFR
visualization
Results of analysis
U M
Dazzi et al. [10] 1989 152 IHC NS NS
Veale et al. [36] 1993 19 PCR S * S
Volm et al. [38] 1993 121 (SqCLC) IHC S * S
Giatromanolaki et al. [18] 1996 107 IHC NS NS
Pfeiffer et al. [31] 1996 186 IHC NS NS
Pastorino et al. [30] 1997 137 (pT1N0) IHC S * S
Rusch et al. [33] 1997 96 IHC S ** NS
Fontanini et al. [12] 1998 195 IHC NS NS
Pfeiffer et al. [32] 1998 190 IHC NS NS
Fu et al. [15] 1999 158 IHC NS NS
Cox et al. [9] 2000 169 IHC NS NS
Brabender et al. [4] 2001 83 PCR NS NS
Cox et al. [8] 2001 167 IHC NS NS
U - univariate, M - multivariate, S - significant, NS - not significant, IHC - immunohistochemistry, PCR polymerase chain reaction; 
* high level of EGFR expression indicates shorter overall patients’ survival; ** low level of EGFR expression indicates shorter overall pa-
tients’ survival
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One should not be surprised that high expression of
EGFR is correlated with progression of malignant dis-
ease. It is well known that lung cancer is a multistep
mutational process in which overexpression of EGFR is
a common alteration. It may be observed in preinvasive
bronchial epithelium, in the thickened basal cell zone of
basal cell hyperplasia and in carcinoma in situ [14].
Additionally, activation of EGFR may lead to cell pro-
liferation, metastases, angiogenesis and reduction of
apoptosis [14]. In this context, it is difficult to explain
why low EGFR expression predicts shorter survival.
However, we have to remember that the family of EGFR
genes includes 4 oncogenes: EGFR/HER1/Erb B-1,
HER2/Erb B-2, HER3/Erb B-3 and HER4/Erb B-4, and
not only EGFR level but also other EGFR family mem-
bers are overexpressed in lung cancer and premalignacy
[14]. Therefore, in the group of tumours with low EGFR
expression and poor prognosis, overexpression of other
EGFR family members might be responsible for conver-
sion of cancer cell into a more aggressive phenotype.
We have found higher EGFR LI in tumours from
patients who later suffered from loco regional recur-
rence than in tumours from patients who later developed
metastases. Similarly, in NSCLC, Lai et al. [22], found
relationship between the expression of ErbB-1 and
ErbB-3 and higher risk of loco regional recurrence, and
between the expression of ErbB-3 and higher risk of
metastases. Those results might suggest that in lung can-
cers, EGFR (ErbB-1) is involved in local tumour growth
processes, while ErbB-3 (not ErbB-1) in the processes of
metastasis formation. These observations might indicate
that different members of EGFR family are involved in
different processes of tumour progression.
We conclude that the problem of prognostic signific-
ance of EGFR expression in lung cancer is far from
being resolved. However, as shown for head and neck
tumours, overexpressed EGFR might be a valid target
for cancer therapy. The two most extensively tested
strategies involve monoclonal antibodies against EGFR
(for example IMC-C225) and inhibitors of the receptor
tyrosine kinase (ZD1839). They can be applied alone or
in combination with chemotherapy [23, 24]. There is a
need for further studies considering not only the level of
EGFR expression but also other parameters that may be
connected with signalling via EGF receptor.
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